Suppr超能文献

在 Emulate® Liver-Chip 中共培养人原代肝细胞和非实质肝细胞以研究药物性肝损伤。

Co-Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver-Chip for the Study of Drug-Induced Liver Injury.

机构信息

National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, Arkansas.

Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration, Silver Spring, Maryland.

出版信息

Curr Protoc. 2022 Jul;2(7):e478. doi: 10.1002/cpz1.478.

Abstract

Drug-induced liver injury (DILI) is a significant public health issue, but standard animal tests and clinical trials sometimes fail to predict DILI due to species differences and the relatively low number of human subjects involved in preapproval studies of a new drug, respectively. In vitro models have long been used to aid DILI prediction, with primary human hepatocytes (PHHs) being generally considered the gold standard. However, despite many efforts and decades of work, traditional culture methods have been unsuccessful in either fully preserving essential liver functions after isolation of PHHs or in emulating interactions between PHHs and hepatic nonparenchymal cells (NPCs), both of which are essential for the development of DILI under in vivo conditions. Recently, various liver-on-a-chip (Liver-Chip) systems have been developed to co-culture hepatocytes and NPCs in a three-dimensional environment on microfluidic channels, enabling better maintenance of primary liver cells and thus improved DILI prediction. The Emulate® Liver-Chip is a commercially available system that can recapitulate some in vivo DILI responses associated with certain compounds whose liver safety profile cannot be accurately evaluated using conventional approaches involving PHHs or animal models due to a lack of innate immune responses or species-dependent toxicity, respectively. Here, we describe detailed procedures for the use of Emulate® Liver-Chips for co-culturing PHHs and NPCs for the purpose of DILI evaluation. First, we describe the procedures for preparing the Liver-Chip. We then outline the steps needed for sequential seeding of PHHs and NPCs in the prepared Liver-Chips. Lastly, we provide a protocol for utilizing cells maintained in perfusion culture in the Liver-Chips to evaluate DILI, using acetaminophen as an example. In all, use of this system and the procedures described here allow better preservation of the functions of human primary liver cells, resulting in an improved in vitro model for DILI assessment. © 2022 Wiley Periodicals LLC. This article has been contributed to by US Government employees and their work is in the public domain in the USA. Basic Protocol 1: Liver-Chip preparation Basic Protocol 2: Seeding primary human hepatocytes and nonparenchymal cells on Liver-Chips Basic Protocol 3: Perfusion culture for the study of acetaminophen-induced liver injury.

摘要

药物性肝损伤(DILI)是一个重大的公共卫生问题,但由于物种差异和新药批准前研究中涉及的人类受试者相对较少,标准的动物试验和临床试验有时无法预测 DILI。体外模型长期以来一直被用于辅助 DILI 预测,原代人肝细胞(PHH)通常被认为是金标准。然而,尽管进行了许多努力和几十年的工作,传统的培养方法在分离 PHH 后完全保留 PHH 的基本肝脏功能方面,或在模拟 PHH 与肝非实质细胞(NPC)之间的相互作用方面都不成功,这两者对于在体内条件下发展 DILI 都是必不可少的。最近,各种肝芯片(Liver-Chip)系统已经被开发出来,用于在微流控通道的三维环境中共同培养肝细胞和 NPC,从而更好地维持原代肝细胞,并因此提高 DILI 预测能力。Emulate® Liver-Chip 是一种商业上可获得的系统,它可以重现某些与某些化合物相关的体内 DILI 反应,这些化合物由于缺乏天然免疫反应或物种依赖性毒性,其肝脏安全性特征不能通过使用涉及 PHH 或动物模型的传统方法准确评估。在这里,我们描述了使用 Emulate® Liver-Chip 共同培养 PHH 和 NPC 用于 DILI 评估的详细程序。首先,我们描述了制备 Liver-Chip 的程序。然后,我们概述了在准备好的 Liver-Chips 中顺序接种 PHH 和 NPC 所需的步骤。最后,我们提供了一个使用在 Liver-Chips 中维持的细胞评估 DILI 的方案,以对乙酰氨基酚为例。总之,使用该系统和这里描述的程序可以更好地保存人原代肝细胞的功能,从而为 DILI 评估提供更好的体外模型。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验